ICS

DRUG4 trials

Sponsors

Novartis Pharmaceuticals, KU Leuven, Boehringer Ingelheim, Chronic Obstructive Pulmonary Disease Trial Network, Denmark

Conditions

AsthmaAzithromycinCOPDCOPD ExacerbationChronic Obstructive Pulmonary DiseaseInhaled CorticosteroidOverlap SyndromePneumonia

Phase 4

Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen

CompletedNCT01985334

Novartis PharmaceuticalsCOPD

Start: 2014-02-14End: 2016-04-29Updated: 2019-03-19

Eosinophil-guided Reduction of Inhaled Corticosteroids

CompletedNCT04481555

Chronic Obstructive Pulmonary Disease Trial Network, DenmarkAzithromycin, COPD, COPD Exacerbation +2

Start: 2021-06-28End: 2025-11-19Updated: 2026-01-28

Unknown Phase

Systematic Approach for the Diagnosis and Treatment of Obstructive Lung Diseases

KU LeuvenAsthma, Chronic Obstructive Pulmonary Disease, Overlap Syndrome

Start: 2015-07-31End: 2021-07-31Updated: 2020-04-08

Tiotropium Plus Olodaterol vs Inhaled Corticosteroids (ICS) Regimens in the Portuguese Primary Care Setting (TIOLCOR Study)

WithdrawnNCT04402515

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2021-10-28End: 2022-01-31Updated: 2021-11-05

Related Papers

Study protocol: COPD-eosinophil-guided reduction of inhaled corticosteroids (COPERNICOS) : A randomized, double-blinded, multicenter, four-arm intervention clinical trial on eosinophil-guided time-updated person-specific reduction of inhaled corticosteroid therapy and prophylactic low dose Azithromycin therapy in patients with severe or very severe chronic obstructive pulmonary disease (COPD).

2025-09-02

Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.

2018-04-1613 citations

Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial

Respiratory Research2017-07-1854 citations